Treatments that suppress ER stress in the airways such as pharmacological chaperones may provide novel therapeutic avenues to reduce TSLP release, making them a relatively low-cost potential treatment for severe asthma or potentially in the setting of acute asthma exacerbations triggered by virus infections, in uncontrolled asthma. The gene discussed is TSLP; the disease is viral infectious disease.